Fortress Biotech (FBIO) AI Stock Analysis

• Market Cap: $57.07M
• Dividend Yield: N/A
• Average Volume (3M): 225.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: -32.11%
• EPS Growth: 88.12%
• Country: US
• Employees: 101
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 29,569,920
• 10 Day Avg. Volume: 223,202
• 30 Day Avg. Volume: 225,897
• PEG Ratio: -0.06
• Price to Book (P/B): 2.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.64
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 0.15
• Enterprise Value/Gross Profit: 1.03
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: $10.00
• Price Target Upside: 418.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $2.00 ▲(3.63%Upside)

Fortress Biotech's overall score is primarily affected by its poor financial performance, characterized by negative earnings and high leverage. Although a recent merger provides a positive outlook for future cash inflows, technical indicators are neutral, and valuation metrics are weak due to negative earnings. The merger event slightly improves the outlook, but significant financial challenges remain.

Fortress Biotech Business Overview & Revenue Model

Company Description

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

How the Company Makes Money

Fortress Biotech makes money primarily through the commercialization of its pharmaceutical and biotechnology products, which are developed either in-house or through its subsidiaries. The company generates revenue from product sales, royalties, and milestone payments from its partnerships and collaborations with other pharmaceutical firms. Additionally, Fortress Biotech may receive licensing fees from out-licensing its technology or products to third parties. Strategic collaborations and partnerships play a significant role in expanding its market reach and enhancing the value of its product pipeline.

Fortress Biotech Financial Statement Overview

Summary

Fortress Biotech demonstrates financial instability with declining revenues, persistent losses, and high leverage. Despite a high gross profit margin, the company's profitability metrics are significantly negative. The balance sheet suggests liquidity and solvency risks due to substantial debt levels. Negative cash flows raise concerns about sustaining operations without external financing.

Income Statement

Fortress Biotech has experienced a challenging financial period with declining revenues from 2023 to 2024, and persistent net losses. The gross profit margin remains positive at approximately 100% due to negligible cost of goods sold, but the company faces a negative EBIT and EBITDA margin, indicating operational inefficiencies. The net profit margin is significantly negative, reflecting high net losses relative to total revenue. Revenue growth was negative in the latest year, indicating a contraction in sales.

Balance Sheet

The balance sheet shows high leverage with a debt-to-equity ratio indicating significant reliance on debt financing. Stockholders' equity has decreased over time, impacting the equity ratio negatively. The return on equity is negative due to continuous net losses, suggesting poor return on shareholders' investments. The current debt levels could pose a risk if profitability does not improve.

Cash Flow

The cash flow analysis reveals negative operating cash flows, indicating that the company is not generating sufficient cash from operations to cover its expenses. Free cash flow is also negative, pointing to challenges in creating value for shareholders. The operating cash flow to net income ratio is unfavorable due to significant cash outflows and net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.67M	84.51M	75.74M	68.79M	45.60M
Gross Profit	36.80M	61.62M	44.97M	36.71M	31.00M
EBITDA	-104.49M	-135.72M	-190.47M	-146.17M	-87.82M
Net Income	-46.00M	-60.64M	-86.58M	-64.70M	-46.53M
Balance Sheet
Total Assets	144.22M	167.53M	294.30M	396.50M	328.83M
Cash, Cash Equivalents and Short-Term Investments	57.26M	80.93M	178.27M	305.74M	233.35M
Total Debt	75.96M	88.59M	127.34M	74.98M	89.08M
Total Liabilities	145.87M	165.94M	244.28M	170.63M	131.84M
Stockholders Equity	22.74M	22.54M	41.72M	108.67M	100.34M
Cash Flow
Free Cash Flow	-95.19M	-136.32M	-182.46M	-132.89M	-90.85M
Operating Cash Flow	-80.19M	-128.22M	-179.40M	-116.54M	-83.68M
Investing Cash Flow	-15.00M	-2.10M	-22.93M	40.51M	-7.16M
Financing Cash Flow	70.64M	32.74M	75.32M	148.99M	172.41M

Fortress Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBIO, the sentiment is Positive. The current price of 1.93 is above the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.87, and above the 200-day MA of 1.78, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 52.40 is Neutral, neither overbought nor oversold. The STOCH value of 54.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBIO.

Fortress Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
BLUE	51 Neutral	$48.67M	―	-546.55%	―	127.51%	56.94%
DTIL	50 Neutral	$54.78M	2.40	-50.81%	―	-11.11%	79.74%
FBIO	48 Neutral	$57.07M	―	-181.84%	―	-32.11%	88.12%
MAIA	44 Neutral	$50.61M	―	-1131.02%	―	―	23.55%
CYCC	38 Underperform	$22.18M	―	-1949.77%	―	-89.76%	80.28%
IMRX	27 Underperform	$147.54M	―	-102.48%	―	―	-7.78%

Fortress Biotech Corporate Events

AstraZeneca’s Anselamimab Trial Shows Mixed Results

On July 16, 2025, AstraZeneca announced that its Phase III clinical trial for anselamimab, a treatment for AL amyloidosis originally developed by Caelum Biosciences, did not achieve statistical significance for its primary endpoint in certain patient stages. Despite this, the drug showed clinically meaningful improvements in a specific subgroup and was well tolerated, prompting AstraZeneca to continue evaluating the results and plan further discussions with global health authorities.

The most recent analyst rating on (FBIO) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.

Fortress Biotech’s Subsidiary Merges with Sun Pharma

On May 30, 2025, Fortress Biotech‘s subsidiary, Checkpoint Therapeutics, merged with Sun Pharmaceutical Industries, resulting in Checkpoint becoming a wholly-owned subsidiary of Sun Pharma and deconsolidated from Fortress. This transaction provides Fortress with $28 million in cash and potential additional earnings through a regulatory milestone and royalty payments, impacting its financial structure and future revenue streams.

The most recent analyst rating on (FBIO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.